Patents by Inventor Yutaka Waki
Yutaka Waki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180221377Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: March 1, 2018Publication date: August 9, 2018Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20170196872Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 24, 2017Publication date: July 13, 2017Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20140249166Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: March 27, 2014Publication date: September 4, 2014Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20120122897Abstract: Methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof and methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. Also, methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA with an effective amount of one or more adenosine A2A receptor antagonists, optionally with a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: November 16, 2011Publication date: May 17, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Patent number: 7727993Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: GrantFiled: January 6, 2006Date of Patent: June 1, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Patent number: 7727994Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: GrantFiled: January 6, 2006Date of Patent: June 1, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20060178379Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 6, 2006Publication date: August 10, 2006Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20060148827Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 6, 2006Publication date: July 6, 2006Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana
-
Publication number: 20040198753Abstract: The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine A2A receptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine A2A receptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine A2A receptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor.Type: ApplicationFiled: January 28, 2003Publication date: October 7, 2004Inventors: Hiroshi Kase, Akihisa Mori, Yutaka Waki, Yutaka Ohsawa, Akira Karasawa, Yoshihisa Kuwana